Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 225 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III... September 11, 2020 As Rates of Some Cancers Increase in Younger People, Researchers Search... May 14, 2025 Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer May 25, 2018 No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia July 30, 2021 Load more HOT NEWS Test Detects Early Signs of Remaining Cancer in Kids Treated for... Should People Over Age 75 Be Screened for Colorectal Cancer? At NCI, A Robust and Rapid Response to the COVID-19 Pandemic p53 Mutations May Differentially Affect Survival of Patients with mCRC Based...
